Evidence mapPaperPMID 37818339Full record

ReviewFrontiers in nutrition2023

Mechanism of the antidiabetic action of

Arslan Shaukat, Arsalan Zaidi, Haseeb Anwar, Nadeem Kizilbash

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Therapeutic efficacy ofFrontiers in nutrition · 2025
    Review
  11. Advances in essential oils for metabolic diseases.Frontiers in endocrinology · 2025
    Review
  12. Identification of Black Cumin (Plants (Basel, Switzerland) · 2024
    Article
  13. Review
  14. Chronic Treatment withInternational journal of molecular sciences · 2024
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Arslan ShaukatDepartment of Physiology, Government College University - GCU, Faisalabad, Punjab, Pakistan.
Arsalan ZaidiNational Probiotic Laboratory, National Institute for Biotechnology and Genetic Engineering College - NIBGE-C, Faisalabad, Punjab, Pakistan.
Haseeb AnwarDepartment of Physiology, Government College University - GCU, Faisalabad, Punjab, Pakistan.
Nadeem KizilbashDepartment Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
Government College University, Faisalabad · PKNational Institute for Biotechnology and Genetic Engineering · PKNorthern Border University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Long used in traditional medicine, Methods: This literature review drew on databases such as Google Scholar and PubMed and various gray literature sources using search terms like the etiology of diabetes, conventional versus herbal therapy, subclinical pharmacology, pharmacokinetics, physiology, behavior, and clinical outcomes. Results: The efficiency and safety of NS in diabetes, notably its thymoquinone (TQ) rich volatile oil, have drawn great attention from researchers in recent years; the specific therapeutic dose has eluded determination so far. TQ has anti-diabetic, anti-inflammatory, antioxidant, and immunomodulatory properties but has not proved druggable. DM's intimate link with oxidative stress, makes NS therapy relevant since it is a potent antioxidant that energizes the cell's endogenous arsenal of antioxidant enzymes. NS attenuates insulin resistance, enhances insulin signaling, suppresses cyclooxygenase-2, upregulates insulin-like growth factor-1, and prevents endothelial dysfunction in DM. Conclusion: The interaction of NS with mainstream drugs, gut microbiota, and probiotics opens new possibilities for innovative therapies. Despite its strong potential to treat DM, NS and TQ must be examined in more inclusive clinical studies targeting underrepresented patient populations.

Indexed as

anti-glycemicantioxidantdiabetes mellitusgut microbiotaNigella sativathymoquinone

Identifiers

PMID37818339
PMCPMC10561288
OpenAlexW4387057347

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.